Nuvaring (Ethinylestradiol, Etonogestrel)

• NuvaRing, a combined estrogen‑progestogen contraceptive, is used to prevent pregnancy.
• Contraception: provides effective reversible birth control to prevent pregnancy in women of reproductive age.
• Family planning: enables women to plan and space pregnancies according to personal goals.
• Hormonal birth control: delivers continuous low‑dose hormones to suppress ovulation and alter cervical mucus.

• Ethinylestradiol and etonogestrel act synergistically; ethinylestradiol binds estrogen receptors, stabilizing the endometrium and increasing cervical mucus viscosity, while etonogestrel, a progestogen, binds progesterone receptors to inhibit the mid‑cycle luteinizing hormone surge, thereby preventing ovulation. Together they create an environment unsuitable for fertilization and implantation.

NuvaRing may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects

• Headache: mild to moderate pain often occurring during the initial cycles.
• Nausea: occasional stomach upset that usually resolves with continued use.
• Breast tenderness: swelling or discomfort of the breasts.
• Vaginal irritation: itching or discharge at the insertion site.
• Mood changes: fluctuations in emotional state or irritability.
• Spotting or breakthrough bleeding: irregular light bleeding between cycles.

Serious or Rare Side Effects

• Venous thromboembolism: deep vein thrombosis or pulmonary embolism, requiring immediate medical attention.
• Hepatic dysfunction: jaundice, liver enzyme elevation, or cholestasis.
• Severe allergic reaction: rash, swelling, or anaphylaxis.
• Hypertension: significant increase in blood pressure.
• Cardiovascular events: stroke or myocardial infarction in high‑risk individuals.

• Before prescribing NuvaRing, clinicians should consider several precautionary measures to ensure patient safety.
• Contraindicated in pregnancy: the product must not be used by women who are pregnant.
• History of thromboembolic disorders: avoid use in patients with past blood clots.
• Current estrogen‑containing therapy: do not combine with other estrogen products.
• Breast cancer history: contraindicated in women with active or past breast cancer.
• Smoking in women over 35 years: increased risk of cardiovascular events.
• Store at room temperature: keep in original packaging, protect from moisture and heat.

NuvaRing can interact with other medicines, altering its effectiveness or increasing side‑effect risk.

Major Interactions (Avoid)

• Rifampin, carbamazepine, phenytoin: enzyme inducers that may markedly reduce contraceptive efficacy.
• Ketoconazole, itraconazole: potent CYP3A4 inhibitors that can increase hormone levels and risk of adverse events.
• Protease inhibitors (e.g., ritonavir): may elevate plasma concentrations of ethinylestradiol.

Moderate Interactions (Monitor Closely)

• Antibiotics such as tetracycline or metronidazole: may slightly diminish contraceptive effect.
• Herbal supplements (e.g., St. John’s wort, ginseng): could reduce hormone levels.
• Antidepressants (SSRIs): may increase risk of mood‑related side effects.
• Antifungal azoles (e.g., fluconazole): may modestly raise hormone exposure.
• Antihypertensives (e.g., ACE inhibitors): monitor blood pressure changes.